论文部分内容阅读
尿激酶型纤溶酶原激活系统是纤溶系统的重要组成部分,其通过水解细胞外间质,参与组织改造和细胞迁移,在肿瘤细胞的侵袭和转移中发挥作用。许多研究发现,尿激酶型纤溶酶原激活系统与卵巢癌恶性程度、分期、分化、转移及预后有重要关系。抑制尿激酶型纤溶酶原激活剂(uPA)的活性、阻断尿激酶型纤溶酶原激活与其受体在细胞表面结合、抑制信号传导途径等可作为卵巢肿瘤治疗的另一途径。综述尿激酶型纤溶酶原激活系统组成、作用机制,与卵巢肿瘤及其治疗研究进展。
The urokinase-type plasminogen activator system is an important part of the fibrinolytic system and plays a role in tumor cell invasion and metastasis by hydrolyzing extracellular matrix, participating in tissue remodeling and cell migration. Many studies have found that urokinase-type plasminogen activator system and ovarian cancer malignancy, staging, differentiation, metastasis and prognosis are important. Inhibition of urokinase-type plasminogen activator (uPA) activity, blocking urokinase-type plasminogen activator and its receptor in the cell surface binding, inhibition of signal transduction pathway can be used as another way of ovarian cancer treatment. This review summarizes the composition and mechanism of urokinase-type plasminogen activator and its progress in the treatment of ovarian tumors.